These findings suggest that modulating endogenous H2S production or administering H2S donors like NaHS could offer a novel therapeutic strategy for PAH by upregulation of the COX-2/PGI2 axis (Li et al., 2014). The gene discussed is PTGS2; the disease is pulmonary arterial hypertension.